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ABSTRACT  
 
Tissue Diagnostics is the world of pathologists, and it is increasingly becoming digitalized 
to leverage the enormous potential of personalized medicine and of stratifying patients, 
enabling the administration of modern therapies. Therefore, the daily task for pathologists 
is changing drastically and will become increasingly demanding, in order to take 
advantage of the development of modern computer technologies. The role of pathologist 
has rapidly evolved from exclusively describing the morphology and phenomenology of a 
disease, to becoming a gatekeeper for novel and most effective treatment options. This is 
possible based on the retrieval and management of a wide range of complex information 
from tissue or a group of cells and associated meta-data. Intelligent and self-learning 
software solutions can support and guide pathologists to score clinically relevant decisions 
based on the accurate and robust quantification of multiple target molecules or surrogate 
biomarker as companion or complimentary diagnostics along with relevant spatial 
relationships and contextual information from digital H&E and multiplexed images. With the 
availability of multiplex staining techniques on a single slide, high-resolution image 
analysis tools and high-end computer hardware, machine and deep learning solutions now 
offer diagnostic rulesets and algorithms that still require clinical validation in well-designed 
studies. Before entering the clinical practice, the "human factor“ pathologist needs to 
develop trust into the output coming from the “digital black box of computational 
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pathology”, including image analysis solutions and artificial intelligence algorithms to 
support critical clinical decisions which otherwise would not be available.  
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Digitalization and intelligent data processing are playing increasingly important roles in the 
practice of histopathology. Consequently, traditional histopathology is gradually being 
transformed into a digital discipline whereby whole-slide scanners can capture images for 
further computer-assisted analyses. Algorithms can extract as much information from 
tissue and standardize the quantification of specific histopathological features, since it 
appears that it is no longer sufficient to exclusively classify cancers just on the basis of 
morphology and genomic profile. Rather, it is essential that the pathologist also accurately 
measures the quantity and dimensions of different critical components in the tissue and 
then links such parameters to all other patient’s and available meta-data.  
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The comprehensive extraction of disease-related knowledge allows educated decisions on 
the precise individual prognosis and the selection of the best available treatment at that 
time. Today, open-source or proprietary software solutions allow pathologists not only to 
manage available information, but also obtain more actionable information and relevant 
insights when applying appropriate techniques. Machine learning will also guide future 
decisions in clinical histopathology as the computer itself also learns to exclude tissue- and 
image-based artefacts while including “regions of interest” (RoI) to answer relevant clinical 
questions.  
 
Until today most commonly the clinically available software in a clinical histopathology 
laboratory is usually a validated information and management system (LIMS) that builds 
the communication interface between different clinical departments, outside contractors or 
analytical partners for tasks, performance and result management. The transition from a 
simple LIMS environment into a fully digital histopathology lab (maintaining the LIMS 
connectivity) requires the digitization of images as well as data and availability of 
significant virtual storage space. However, despite this disruption, digital histopathology 
allows entry into a new era of clinical decision making based on accumulation of big data 
to use advanced solutions, such as machine and deep learning tools generating novel 
clinical insights. Histopathologists have begun to resume different and more complex tasks 
that are almost impossible to achieve without software assistance.  
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The origin of digital pathology lies in the area of telepathology to share images across long 
distances for a remote second or expert opinions [1]. Pathologists have used 
telepathology effectively driving a microscope remotely for several decades [2], and now 
they are making further use of its applications.  The field of digital histopathology is 
currently following technical advancements with its rapid transitioning from primarily a 
research tool into a viable clinical solution for patient primary diagnosis and the 
determination of prognosis. The use of such tools also allows for the discovery of novel 
features [3].  
The success of digital pathology also relies on the availability technically sophisticated 
viewing devices and the entire infrastructure within the clinical setting according to 
regulatory standards. This includes whole-slide scanners, laboratory information systems, 
the digital archiving of specimens, and, of course, the willingness of histopathologists to 
quickly adopt clinically validated software. 
The concept of ‘personalized’ or ‘precision’ medicine, stratifying patients to the best 
available treatment according to diagnostic test results, has been built over the past 
decades. While genomic and gene expression analysis still represent a large proportion of 
“biomarker” tests, the analysis of tissue images is actually very well-suited to address 
complex biological questions especially in oncology.  
 
Image mining software solutions can assist histopathologists in identifying RoI for further 
thorough exploitation, document the complete survey of the digitized image as part of a 
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certification-related quality measure, or to understand tumour heterogeneity in its entirety. 
In the dawning age of immunotherapies and complex combination treatments, along with 
cancer-specific scoring algorithms on different platforms that are linked to selected drugs 
and concordant molecular parameters, validated software solutions guide the decisions of 
the pathologist without depriving them of the role as the ultimate diagnostic authority.  
 
There is still uncertainty amongst clinical histopathologists about the use of digital 
pathology, and perhaps there is a nervous perception that terminology and software 
applications in histopathology are difficult. Pathologists question what kind of solutions are 
of true value in the daily personal clinical practice and which are research-use only (RUO) 
applications.  Has the tool or the solutions been validated or even approved by the 
authorities or notified bodies? Is the decision supported by the software or associated 
algorithms even more confusing or distracting when trying to conclude and sign-off a 
difficult clinical case, or are they indeed even misleading or plainly wrong?  Is the software 
proprietary or an open-source product, and for what purpose and intended use? In the 
end, it is still the pathologist who signs out the case, and also takes full responsibility of 
any secondary action. The learning curve for pathologists and software engineers for the 
routine application of digital histopathology is still present and steep. One aim is to develop 
a mutually understandable language and nomenclature to agree to a common goal and 
the same meaning. A “solution” can have a different meaning for a clinician and for a 
software developer. In this publication, we follow the recommendation and suggestion of 
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the White Paper of members of the Digital Pathology Association (DPA) [4]. The term 
“computational pathology” (CPATH) is used in the context of digital pathology and goes 
beyond the simple digitization of stained slides and the inspection of tissue images on a 
computer screen. CPATH implies already an expansion of the normal viewing fields (e.g. 
via microscopy) because it allows the simultaneous inspection of various stains along with 
accompanying meta data, such as expression and/or sequencing data, or the tumour 
mutational burden which is currently under evaluation as a molecular surrogate to predict 
the clinical response to immune modulating agents.   
 
THE CHALLENGES IN HISTOPATHOLOGY  
 
Over the past 10 years, the pathology community experienced disruptive changes in the 
practice of histopathology and the consequences of its action. Although the US Food and 
Drug Agency (FDA) stated even in 2004 it would disapprove any novel drug without a 
biomarker assay under development or at least an existing biomarker strategy, we have 
only recently experienced the serious effects of this decision. Today, treatment decisions 
are still mainly achieved by histological investigations of individual cell populations. 
However, in the future, the study of networks of cells, their contextual relationship and 
even spatial genomics empowered by software solutions and AI-assisted algorithms will 
bring these decisions to a newer level. With the ability to measure and directly target 
checkpoint molecules, such as CTLA-4 and the PD-1/PDL-1 axis, to unleash a specific 
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anti-cancer immunity, the need for specific testing of the individual immune status in 
individual cancer types has become mandatory for most histopathology laboratories.  But 
the complexity of measuring PD-1 and / or PD-L1 has by far excelled the testing for 
Her2/neu or any hormonal receptor in breast or prostate cancer, independent of the 
available staining platform or robust manual processes in place. Even expert 
histopathologists have to be trained on the correct reading and reporting of the different 
PD-1 / PD-L1 antibodies provided by different vendors, with the scores being dependent 
on the stage of disease and line of treatment. Sometimes it is “sufficient” to score the 
individual case “positive” in case of more than 25% PD-L1 positive cancer cells. In different 
indications, counting the absolute numbers of invasive cancer cells plus any PD-1 positive 
immune cells (sometimes even tumour-infiltrating lymphocytes versus macrophages or 
other immune cells) above 1% are considered a positive score. Consequentially, the 
accurate measure of checkpoint inhibitors in different tissue compartments (e.g. tumour-
stroma) is of essential importance to select the best therapy option for an individual patient 
and might therefore warrant an automated PD-1 / PD-L1 scoring solution.  
Although it has been shown that an experienced and well-trained histopathologist can 
generate correct scoring results manually without any technical assistance, it takes a 
considerable amount of time, and such cases will become even more complex in the 
future. Jerome Galon and his team already demonstrated with the “ImmunoScore” for 
Colon Cancer that only two different immune markers (CD3 and CD8) in different tissue 
compartments (invasive margin versus tumour centre) provide a significant progress on 
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the prognosis in limited versus advanced disease [5,6]. This was supported by a validated 
software solution that identified the different regions automatically and quantified the 
spatial ratio of immune cells in the different compartments [7].  
 
Increasingly, software-assisted tools play a crucial role in the stratification of patients to 
certain therapies in the age of immunotherapies and beyond. The reasons are manifold: 
the increasing understanding of disease complexity and the so far underestimated role of 
tumour heterogeneity and its microenvironment. Figure 1 schematically demonstrates the 





SOLUTIONS THROUGH SOFTWARE-ASSISTED IMAGE ANALYSIS   
 
It was more than three decades ago, when pathologists were first offered assistance to 
count Ki-67-positive cells. At that time, there was still a significant gap between the 
capabilities of the available soft- and hardware compared to the intuitive competence and 
skill sets of well trained and experienced pathologists. The next challenge was to count 
mitotic figures, which not only had a prognostic value but could also determine malignancy 
with radical therapeutic consequences. Even today, software solutions still struggle to 
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reliably discriminate between a true mitosis or some wizened, clump of chromatin due to 
an activated apoptosis pathway or fixation artefact. This “mystery” is still not completely 
solved, independent of the use of sophisticated immunostainings related to cell cycle 
phases and different machine / deep learning attempts, which were subject to several 
grand challenges [9]  
The success of the HER2/neu scoring “algorithm” as a first predictive digital biomarker 
about twenty years ago was rather an accomplishment of a community of pathologists who 
understood the need to optimally stratify patients with breast cancer and a single 
biopharmaceutical company that did their utmost to train and educate the practicing 
histopathologists. A HER2/neu scoring algorithm was the first to receive regulatory 
approval as an in-vitro diagnostic medical device. This strategy is still successfully 
deployed in the age of combination immunotherapies [10,11].  
 
On the road to better diagnoses and combination therapies, the availability of different 
multiplex assays adds another mostly overwhelming level of insights but also complexity to 
the pathologists’ arsenal [12]. While tools like the molecular profiling or the mutational 
burden are very helpful to identify a plethora of potential diagnostic hints or therapeutic 
targets, they all lack spatial context and relevant contextual information that is often 
necessary to understand the complete tumour microenvironment. Software solutions as an 
integral part of image analysis tools can assist the pathologist to understand the multiplex 
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images or even virtually mount complex pictures to visualize the true nature of a tumour in 




SOFTWARE-ASSISTED ANNOTATION AND SEGMENTATION  
 
The development of artificial intelligence (AI) has in part been shaped by the field of 
neuroscience and other non-medical applications. By understanding the human brain, 
scientists have attempted to build new intelligent machines capable of performing complex 
tasks. While the development of artificial intelligence algorithms has been fast paced, the 
actual use of most software algorithms in clinical practice is still markedly below its 
conceivably broader potentials also in histopathology. This is partly because for any 
algorithm to be incorporated into existing or future workflows, it has to stand the test of 
thorough scientific validation and robust clinical utility without causing any harm or 
confusing the human factor. In this context, there is much to be gained by combining AI 
and the human intelligence of experienced pathologists. Harnessing empirical knowledge, 
big data, computing power and storage capacities, and addressing clinical issues demand 
deploying expert knowledge in tandem with AI. Drug discovery and translational 
biopharmaceutical research will also gain from AI technology when humans fail to see 
pivotal next step and the next suitable application. Since the revolutionary success of the 
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deep learning architecture for ImageNet image classification in 2012, the computer vision 
community has seen an exponential growth in convolutional network methodologies, 
architectures and applications. This growth is fuelled by ever-increasing computational 
power, the availability of freely available open-source packages and the availability of 
robust big data [14,15].  
 
At the same time, Digital Pathology has been recognized as one of the most impactful 
application areas for AI, and headlines such as “Artificial intelligence could yield more 
accurate breast cancer diagnoses” [16] will certainly be followed by medical products 
implemented in daily clinical routine. The first systems have been already approved by the 
FDA, and Kapil et al published first results in Scientific Reports showing performance 
comparable to well-trained clinicians for an automated PD-L1 scoring solution for lung 
cancer therapy prediction [17].  
 
The “correct annotation” to train any system is still the bottle neck, and the automated 
software solution should be as good as those human experts, who still define the “ground 
truth”. Most digital pathology systems are based on thousands and thousands of cells and 
annotated regions in histopathology images performed by human expert pathologists 
[18,19]. However, there is one way out: Yousefi et al presented in 2017 a scientific paper 
called “Predicting clinical outcomes from large scale cancer genomic profiles with deep 
survival models” [20]. It describes how to predict patient survival with very little biological 
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knowledge, and it opened the way for the research team to apply the published methods 
to whole slide images of our gastric and lung cancer patient cohorts. Other examples 
demonstrate how deep learning can be applied to classify lung cancer and predict 
mutations in lung cancer [21] or microsatellite instability in gastric cancer [22].  
 
Machine learning, like deep learning, is a part of computer science and more precisely 
artificial intelligence that can learn from images and data without requiring the user to 
define explicit rules. Machine learning applications have made tremendous progress in the 
last decades, especially in the fields of image analysis, natural language processing and 
pattern recognition [23–25]. This development has been fostered by the availability of 
large data sets for training these systems as well as reasonably priced computing power, 
especially of graphics processing units (GPUs) [26]. Typical applications include, but are 
not limited to, the detection of RoI, automated tumour-stroma-separation or the detection, 
segmentation, and classification of objects, such as different cell types. Most of those 
tasks can often be achieved easily by humans (being an expert or becoming an expert 
after training). Therefore, the most common tasks in the analysis of digital pathology are 
the detection and segmentation of objects of interest, followed by an accurate 
measurement of staining or defining spatial relationships, which also requires image and 
data organization into training and test sets [27]. However, sometimes knowledge-based 
(“heuristic models”) approach like cognition network solutions [28] are not sufficient to 
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generate novel insights. Instead, reinforced (feature) learning solutions are warranted, and 
their applications are steadily growing (Figure 3).   
 
The continues rise of the machines will trigger significant changes on how 
histopathologists analyse tissue images, profile patients, and derive medical conclusions. 
Besides image analysis, object classifications and well-trained machine-based algorithms, 
a fast-growing body of scientific literature and an increasing number of relevant clinical 
studies is another rich source of knowledge, which requires also emphasis on Natural 
Language Processing (NLP) plus text analysis to leverage all available information. There 
are 700 000 new articles on health care every year, which can no longer be 
comprehended by an individual or group of pathologists. Nowadays a stage is reached 
where, after expending significant effort in labelling (scientific) text, natural language 
sentences can be mapped to a logical form, which can be used in formalized reasoning 
mechanisms to work with these extracted formulas. However, the question remains 
whether the practicing pathologist needs to fully understand how any software comes to a 
certain conclusion coming from text, data, or images and how to trust the conclusion that 
comes from such a “black box”? [29]. Experts stress the need to become more transparent 
on the training of deep learning models and how to apply them at scale across 
increasingly more complex and diverse diagnostic tasks [30]. The path to efficiency will be 
led in part by steps of “small data” and the use of more unsupervised learning due to the 
scarcity of available tissue and good data. While clinical scientists try to make the clinical 
This article is protected by copyright. All rights reserved.
trial formats even more efficient in designing basket, umbrella and platform trials, the 
number of relevant subjects might remain small. Sometimes there simply is not enough 
data available to feed a deep learning model. Since patients do not have the time to wait 
for that researchers are pushing to figure out ways to train systems on less data and are 
confident, they’ll find a viable and clinically trustworthy solution. Current deep learning 
models require datasets that are not only massive but also representative of the relevant 
problem. “Supervised learning” largely relies on pathologists to do the labelling and the 
subject matter expert (e.g. expert pathologist) telling the system everything they know with 
relative certainty. On the other hand, unsupervised learning allows raw unlabelled data to 
be used to train a system with little to no human effort, and one might receive insights that 
are truly new and innovative. The relevance of the in- as well as out-put might be uncertain 
until it is clinically validated. 
 
 
THE HUMAN FACTOR PATHOLOGIST 
 
Pathologists usually struggle with unsupervised learning methods or AI solutions. During 
their course of training they are used to learning from other experienced pathologists, slide 
seminars and scientific conferences. While in recent years most novel biological and 
clinical insights have come from molecular pathology and deep sub-typing of different 
cancer types, now also software solutions enter the perception of histopathologists.  
This article is protected by copyright. All rights reserved.
An automated software solution for histopathology that achieves a performance of 90 
percent may appear to outperform human pathologists. But the conditions are usually not 
quite the identical, so “pathologist versus AI” may not really be the right comparison. 
Instead, pathologists and computers need to work together, each performing to their own 
strengths and controlling each other.  
 
Asking the pathologist to determine the percentage of cells (to be evaluated against a pre-
determined threshold, for example, >25 percent) of a certain cell type (for example, all 
invasive tumour cells) that have any positive staining (for example PD-L1) in a certain cell 
compartment (e.g. tumour versus stroma) that is above an absolute threshold is not an 
uncommon task nowadays, and it seems obvious that manual scoring will lead to high inter 
and intra-pathologist variabilities unless the histopathologists was thoroughly trained and 
maintains a significant level of routine. The pathology practice involved in immuno-
oncology today has to deal with even more stains in different tissue contexts and apply 
more complex scoring schemes (see above). The level of complex analysis required is 
becoming almost impossible for a pathologist using just a microscope. A computer, on the 
other hand, would complete many of these tasks with little difficulty if the used algorithm 
has been designed, trained, and validated properly. With the increasing adoption of digital 
pathology, which enables computers to analyse images of histology slides, it is time to 
allow software to assist and support the pathologist.   
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One of the key problems for any automated system in pathology is the variation between 
samples, the pre-analytical inconsistency. No two examples of a disease look the same – 
even in similar patients under similar conditions. Human pathologists know that only too 
well. The best way is to develop a standard clinical workflow as the perfect intermediate 
step between manual microscopy and automated software solutions. This also requires as 
a first step the integration of true or virtual multiplex staining and software solutions into a 
standardized laboratory environment where possible and suitable (Figure 4).  
 
 
SOFTWARE-ASSISTED DECISIONS IN CLINICAL PRACTICE  
 
Digital Pathology is already now rapidly translating into the clinical practice, facilitating 
multiple advantages compared to traditional histopathology today [31]. Regulatory 
approval and advances in associated technologies including high power computing and 
data storage capabilities along with whole-slide image (WSI) scanners allow large batch 
image capture and the application of deep learning to make informed decisions in 
histopathology [32] Despite all progress in the genomic and post-genomic era [33], the 
importance of spatial localization of gene expression (“spatial genomics”) has been 
recognized as a missing link that provides order to the conundrum of cancer biology. This 
not only allows the translation into clinical development and practice, but also to train the 
future generation of young pathologists and tissue experts [34]. The next generation of 
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domain experts is eager to use the support of software-based solutions especially to error-
prone problems, like Gleason Scoring [35,36] which usually require substantial training or 
identify biomarker signatures that are not too obvious [37,38]. But it still to the discretion of 
the pathology on how and to what extent accept or dismiss the results of a software-based 





Digital pathology is currently proving itself to be a reliable tool in the clinical practice and is 
also becoming a part of the education and training of histopathologists, as well as a critical 
in translational tissue-based research. Although still in its infancy, computational pathology 
in general, and especially software-assisted decision support systems, are here to stay 
and are ‘waiting at the front door’ to enter routine histopathology, given all the challenges 
ahead of pathologists [39,40]. While there are still regulatory and psychological barriers, 
there are multiple reasons for the clinical adoption of this technology, including technical 
advances in the digital technology and the availability of cognitive computing. No 
histopathologist will be replaced by software, but the way to practice histopathology will 
change; digital pathology would be there to augment diagnostics only, as one of the many 
tools used by histopathologists in their diagnostic tool repertoires. The question remains 
when to enter the routine use of clinical software support. Other clinical disciplines have 
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already embraced this ‘disruptive’ technology as the digital interface with the global 
community of domain experts [41], and to allow the real-time accessibility of all available 
data and best solutions for comprehensive patient profiling and optimal therapy matching 





We apologize to all those authors whose excellent work could not be mentioned or 
discussed here. Digital or computational pathology, the field of artificial intelligence and 
software development including novel hardware solutions are so rapidly evolving that any 
article on this subject must have its limitations and many excellent key references cannot 
be cited.  
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Figure 1. Today’s diagnostic challenge in histopathology is the understanding of the entire 
tumour heterogeneity and the complex immune interplay of different stakeholders in 
various compartments. Different groups have shown that it is of pivotal importance to 
precisely locate and accurately quantify immune cells inside (“hot tumour”) and outside 
(“excluded”) and correlate it with the entire area or provide percentages to start doing the 
math. It is an erroneous belief that tumours are only hot, cold or excluded. They can be a 
mixture of all activation states, which might change after treatment or in a metastatic 
setting. It could also be demonstrated that the topology of the spatial relationship of 
activating and modulating cells have a significant influence on different treatment 
modalities and their possible combinations. Only the use of a robust digital image analysis 
and mining solutions allow for the correct assessment of the true complexity and enable 




Figure 2. Most current problems in routine histopathology can be solved with software-
guided image analysis tools. The increasing emergence of complex multiplex analysis 
allow the consideration of the tumour heterogeneity and the spatial relationships of various 
markers (manual attributions are a challenge in terms of robustness and accuracy). If 
single slide multiplexing is not possible due to inconsistent antigen-retrieval or disparate 
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Figure legends 
staining protocols, virtual multiplexing is also an option. Novel Artificial Intelligence (AI) 
solutions allow to reveal even novel and unique signatures from H&E slides which are 
available in abundance. The required hardware such as whole slide imaging (WSI) and 
related scanning devices are currently under regulatory scrutiny and have received 




Figure 3: Simplified scheme on the use of different AI-tools (e.g. cognition network 
language, Bayes network, fuzzy logic, Random Forest, End-to-end solutions) in Machine 
Learning (ML) and related disciplines. Initial INPUT is usually provided by expert 
knowledge from pathologists supported by training data such as digitized images. With 
different level of supervision, active learning algorithms build mathematical models that 
provide OUTPUT solutions, which can be continuously improved by several iterations 
(reinforced learning) until the result becomes explainable (“Explainable AI”) and clinically 
validated. The transition from heuristic models to feature learning should be seamless, 
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Figure 4. Adaption of a single mono- or multi-plex assay as a “lab-developed-test” in a 
CAP / CLIA (accredited according to the College of American Pathologists / Clinical 
Laboratory Improvement Amendments) histopathology lab environment and consecutive 
ruleset development, which still requires clinical validation. This allows the transfer of 
research solutions to enter the diagnostic market in a regulated environment. Alternatively, 
an already validated IVD (in vitro diagnostic) assay can be deployed or manual reading is 
still an option for the expert pathologist to sign out the case. By any means, it is still dual 
path forward for the pathologist to still read the stained slide(s) manually under the 
microscope but also to utilize the computer screen with its cloud-based or locally installed 




Figure 5. Software-guided image analysis [4] is still embedded into a network of quality 
control measures and decision making before a diagnostic recommendation is accepted 
and an individual case is signed out. The recommended decision provided by the software 
(SW) has to be plausible to the experienced pathologists 1. The domain expert can dismiss 
any digital recommendation 2 if a decision is clearly wrong or based on inadequate input 
data or an inappropriate analytical process. The use of any pre-existing ruleset or 
computer algorithm has be carefully assessed for the particular histopathological solution 
prior to any clinical application 3. It might even require a clinical validation step. Different 
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free open-source or commercial proprietary software solutions are readily available to 
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